A Placebo-Controlled, Combined Single and Multiple Rising Dose Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV338 After Intravenous Administration in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2010
At a glance
- Drugs SLV 338 (Primary)
- Indications Cardiovascular disorders; CNS disorders
- Focus Adverse reactions
- 30 Jan 2010 Actual number of patients changed from 43 to 42 as reported by ClinicalTrials.gov record.
- 30 Jan 2010 Actual end date (1 Dec 2009) added as reported by ClinicalTrials.gov record.
- 30 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.